Novavax, Inc.
NVAXBiotechnology
$10.47+1.45%As of Oct 29vs prior close
- Market cap
- $1.7B
- P/E (TTM)
- –
- From 52W high
- −18.33%
- EPS (LTM)
- -$1.35
- Revenue (LTM)
- $413.8M
- Net margin
- -59.87%
- Dividend yield
- 0.00%
Nomior Score
32
Steady ProfileSpeculativeBottom 18% of the scored universe
Growth17
Quality43
Value53
Momentum59
Resilience30
Growth
+61.12%revenue a year over 9 fiscal years
YE16 $15.4MLTM $413.8M
Connections
Revenue to profitQ2 YE26
The operating loss was 97% of revenue, wider by 139 pts on a year.
Who owns it
2funds, 1 tracked portfolio